Related Experiment Video
Updated: Aug 27, 2025
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
20.1K
Pulmonary Hypertension in Scleroderma- Evaluation and Management
Pujitha Vallivedu Chennakesavulu1, Srikar Uppaluri1, Jagadish Koyi2
1Kamineni Academy of medical sciences and research centre, Hyderabad, India.
Disease-A-Month : DM
|September 26, 2022
Summary
Systemic Sclerosis-associated Pulmonary Arterial Hypertension (PAH) is a severe condition. Early screening and diagnosis are vital for improving outcomes in PAH patients with Systemic Sclerosis.
Area of Science:
- Rheumatology and Cardiology
- Autoimmune disease mechanisms
- Pulmonary vascular remodeling
Background:
- Systemic Sclerosis (SSc) is a leading cause of Pulmonary Arterial Hypertension (PAH).
- PAH in SSc involves obliterative vasculopathy and increased pulmonary vascular resistance.
- PAH diagnosis in SSc carries a high mortality rate, necessitating improved management.
Approach:
- Review of current literature on PAH in SSc.
- Focus on screening and diagnostic protocols.
- Exploration of novel therapeutic strategies and prognostic markers.
Key Points:
- SSc-PAH affects nearly 15% of SSc patients.
- Early detection of PAH in SSc is critical due to poor prognosis.
- Research is ongoing for better screening, diagnosis, and treatment.
Conclusions:
- Robust screening and diagnostic protocols are essential for SSc-PAH.
- Advances in treatment and understanding of prognostic indicators are needed.
- Multidisciplinary approaches can improve patient survival and quality of life.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
270
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
270
01:20Rheumatic Heart Disease IV: Nursing Management
33
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
33
01:27Mitral Stenosis IV: Nursing Management
29
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
29
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
247
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
247
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
238
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
238
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K